We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.5B
AUM Growth
+$439M
Cap. Flow
-$3.35M
Cap. Flow %
-0.06%
Top 10 Hldgs %
41.65%
Holding
136
New
22
Increased
21
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$87.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$46.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.6M
4
AMGN icon
Amgen
AMGN
+$38.4M
5
UNH icon
UnitedHealth
UNH
+$37.9M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$74.9M
2
THC icon
Tenet Healthcare
THC
+$59.2M
3
VRNA
Verona Pharma
VRNA
+$41.4M
4
GERN icon
Geron
GERN
+$40.6M
5
PCVX icon
Vaxcyte
PCVX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Miscellaneous 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
126
CALL
DELISTED
Merus
MRUS
– –
-50,000
Closed -$2.96M
MRUS
127
DELISTED
Merus
MRUS
– –
-156,100
Closed -$9.24M
ORIC icon
128
Oric Pharmaceuticals
ORIC
$1.25B
– –
-287,100
Closed -$2.03M
PFE icon
129
CALL
Pfizer
PFE
$157B
– –
-250,000
Closed -$7M
PGNY icon
130
Progyny
PGNY
$2.13B
– –
-259,900
Closed -$7.44M
TGTX icon
131
TG Therapeutics
TGTX
$8.16B
– –
-133,200
Closed -$2.37M
VRNA
132
DELISTED
Verona Pharma
VRNA
– –
-2,861,801
Closed -$41.4M
LSB
133
DELISTED
LakeShore Biopharma
LSB
– –
-140,428
Closed -$910K
MORF
134
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-612,500
Closed -$20.9M
OMIC
135
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
– –
-18,023
Closed -$152K
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2024 Portfolio in Review

As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
  • OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
  • OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
  • OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q3 2024.
  • OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.